Ballow, Mark
Wasserman, Richard L.
Jolles, Stephen
Chapel, Helen
Berger, Mel
Misbah, Siraj A.
Article History
Received: 8 January 2017
Accepted: 6 June 2017
First Online: 10 July 2017
Change Date: 27 April 2018
Change Type: Correction
Change Details: The article Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials, written by Mark Ballow, Richard L. Wasserman, Stephen Jolles, Helen Chapel, Mel Berger, Siraj A. Misbah, was originally published Online First without open access
Compliance with Ethical Standards
:
: Mark Ballow received research grant from CSL Behring (61198060) and an investigator for Grifols, speaker honorarium from American College of Allergy, Asthma and Immunology, Baxalta, Shire, advisory boards and consultant for CSL Behring, Shire, and Grifols, Data Safety Monitoring Boards – Prometic, Green Cross, CSL Behring.Richard L. Wasserman received a speaker honorarium from American College of Allergy, Asthma and Immunology, Shire, Oklahoma Allergy Society, Florida Allergy Society and Intermountain Allergy Society, Consultant for Gerson Lehman Group, Guidepoint Global, Grifols, CSL Behring, Therapure, Prometic, Bioplasma Laboratories and Shire.Stephen Jolles received support for consulting, conferences, and/or research from CSL Behring, Baxalta, Bio Products Laboratory, Biotest AG, Octapharma, Shire, Grifols, LFB Biotechnologies, UCB Pharma and Swedish Orphan Biovitrum AB.Helen Chapel declares that he has no conflict of interest.Mel Berger is a salaried employee of CSL Behring with stock holdings.Siraj A. Misbah’s institution has received honoraria for advisory board membership/lectures/research from BPL, Baxalta, Biotest, CSL Behring and Grifols.